Multiple sclerosis and related disorders · 2026
Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Molenaar P C G, Weir D L, Arnoldus E P J, Beenakker E A C, van den Bos R P M, van Eijk J J J, Feenstra C, van Geel B M, Heersema D J, Hoitsma E, Horvath K M, Killestein J, Kragt J J, van Munster C E P, Snoeijen A H W J M, Wokke B H A, Goettsch W G, Strijbis E M M, de Beukelaar J W K, Kalkers N F, de Jong B A, Dutch-MSR consortium
Аннотация
BACKGROUND: Real-world drug utilization studies provide valuable insights into the treatment of relapsing-remitting multiple sclerosis (RRMS). As treatment dynamics in the Dutch context are limited, we studied drug utilization patterns in the first two years following a RRMS diagnosis in the Netherlands.
METHODS: People diagnosed with RRMS between 2016 and 2022 were included from the Dutch Multiple Sclerosis Registry, a registry-based observational study. Disease modifying therapies (DMTs) were categorized as low-, moderate- or high-efficacy. Initiation, discontinuation, reasons for discontinuation, and switches in the first two years post-diagnosis were evaluated. We calculated proportions with 95% confidence intervals (CI).
RESULTS: We included 806 PwMS. 2-year discontinuation was highest for low- (51%, CI: 45-57) and moderate-efficacy (37%, CI: 32-42) DMTs, mainly due to adverse events or insufficient efficacy. Of those switching from these therapies, 26% (CI: 21-33) switched to low-efficacy and 37% (CI: 30-44) to moderate-efficacy therapies, of which 32% (CI: 34-41) discontinued their second DMT. Anti-CD20 therapies were discontinued in 5% (CI: 2-15) of initiations. High-efficacy DMT use rose from 12% (CI: 10-15) at initiation to 29% (CI: 26-33) at year two.
CONCLUSION: Our results indicate high risks of discontinuation of low- and moderate-efficacy DMTs, in contrast to low risk of discontinuation of anti-CD20 therapies. These findings may give further direction to research on finding the optimal treatment strategy and may inform health care providers in the Netherlands.
METHODS: People diagnosed with RRMS between 2016 and 2022 were included from the Dutch Multiple Sclerosis Registry, a registry-based observational study. Disease modifying therapies (DMTs) were categorized as low-, moderate- or high-efficacy. Initiation, discontinuation, reasons for discontinuation, and switches in the first two years post-diagnosis were evaluated. We calculated proportions with 95% confidence intervals (CI).
RESULTS: We included 806 PwMS. 2-year discontinuation was highest for low- (51%, CI: 45-57) and moderate-efficacy (37%, CI: 32-42) DMTs, mainly due to adverse events or insufficient efficacy. Of those switching from these therapies, 26% (CI: 21-33) switched to low-efficacy and 37% (CI: 30-44) to moderate-efficacy therapies, of which 32% (CI: 34-41) discontinued their second DMT. Anti-CD20 therapies were discontinued in 5% (CI: 2-15) of initiations. High-efficacy DMT use rose from 12% (CI: 10-15) at initiation to 29% (CI: 26-33) at year two.
CONCLUSION: Our results indicate high risks of discontinuation of low- and moderate-efficacy DMTs, in contrast to low risk of discontinuation of anti-CD20 therapies. These findings may give further direction to research on finding the optimal treatment strategy and may inform health care providers in the Netherlands.